UBT251
GIP/GLP-1/GCG · s.c. · United Laboratories (Novo Nordisk licence)
Summary
- Also known as
- United Laboratories
- Mechanism
- GIP/GLP-1/GCG
- Route
- s.c.
- Company
- United Laboratories (Novo Nordisk licence)
- Highest development stage
- phase 3
- Status (as of data cut)
- Phase 3 in China: UNIGUIDE-1 (T2D) recruiting since Sep 2026; obesity and sleep apnoea trials registered; phase 2 (T2D) at EASD 2026 verify
- Next milestone
- Phase 3 results in China (primary completion from Sep 2027)
Sources for the status
- The United Bio-Technology (Hengqin) Co., Ltd.. A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Trial to Evaluate the Efficacy and Safety of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone(UNIGUIDE-1) (UNIGUIDE-1). ClinicalTrials.gov identifier NCT07659574. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT07659574
- The United Bio-Technology (Hengqin) Co., Ltd.. A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of UBT251 Injection in Obese Participants With Moderate-to-severe Obstructive Sleep Apnea (OSA) Not on Positive Airway Pressure (PAP) Therapy(UNISHAPE-OSA-1) (UNISHAPE-OSA-1). ClinicalTrials.gov identifier NCT07767942. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT07767942
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 2 phase 3 ongoing | Phase 2 positive (EASD 2026: up to −19.7 % at 24 weeks); phase 3 ongoing | UBT251 phase 2 obesity (EASD 2026) |
| T2D | 2 phase 3 ongoing | Phase 2 positive (Cell Metabolism, October 2026); phase 3 ongoing | UBT251 phase 2 T2D (EASD 2026); UBT251 phase 2 T2D, Cell Metab 2026 |
| CV outcomes | 0 no data | ||
| CKD | 1 phase 2 / signal | Phase 2 only | |
| HFpEF | 0 no data | ||
| MASH | 1 phase 2 / signal | Phase 2 only | |
| Sleep apnoea | 2 phase 3 ongoing | Phase 3 registered on ClinicalTrials.gov | |
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UBT251 phase 2 (T2D) | UBT251 2.0 mg | t2d china | 24 | — | — | — | −2.2 vs −0.7 | — | — | — | — | — | — | verified |
| UBT251 phase 2 (T2D) | UBT251 6.0 mg | t2d china | 24 | — | — | — | −2.1 vs −0.7 | — | — | — | — | — | — | verified |
| UBT251 phase 2 (obesity) | UBT251 4.0 mg (start 1.0 mg) | obesity china | 24 | — | — | —−19.7 % vs −2.0 % estimand not specified | — | — | — | — | — | — | — | verified |
| UBT251 phase 2 (obesity) | UBT251 6.0 mg | obesity china | 24 | — | — | —−18.7 % vs −2.0 % estimand not specified | — | — | — | — | — | — | — | verified |
| UBT251 phase 2 (obesity) | UBT251 2.0 mg | obesity china | 24 | — | — | —−13.6 % vs −2.0 % estimand not specified | — | — | — | — | — | — | — | verified |
| UBT251 phase 2 T2D China (NCT07163624) | 4.0 mg (initial dose 0.5 mg) vs semaglutide 1 mg: weight -4.8 %, HbA1c -1.77 | t2d china | 24 | 211 | — | — | −2.0 vs −0.7 | — | — | — | — | — | — | congress |
| UBT251 phase 2 T2D China (NCT07163624) | 4.0 mg (initial dose 1.0 mg) vs semaglutide 1 mg: weight -4.8 %, HbA1c -1.77 | t2d china | 24 | 211 | — | — | −2.1 vs −0.7 | — | — | — | — | — | — | congress |
| UBT251 phase 2 obesity China (NCT07177469) | 4.0 mg (initial dose 0.5 mg) | obesity china | 24 | 205 | — | —−16.2 % vs −2.0 % estimand not specified | — | — | — | — | — | — | — | congress |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- UBT251 4.0 mg (start 1.0 mg): Estimand not stated in the abstract (ANCOVA LS means); both models agree Peer-reviewed paper (Cell Metab 2026) confirms the range of −13.6 % to −19.7 % vs −2.0 % with placebo at 24 weeks; per-dose values come from the EASD 2026 abstract until the full text is available.
- UBT251 6.0 mg: Estimand not stated in the abstract (ANCOVA LS means); both models agree Peer-reviewed paper (Cell Metab 2026) confirms the range of −13.6 % to −19.7 % vs −2.0 % with placebo at 24 weeks; per-dose values come from the EASD 2026 abstract until the full text is available.
- UBT251 2.0 mg: Estimand not stated in the abstract (ANCOVA LS means); both models agree Peer-reviewed paper (Cell Metab 2026) confirms the range of −13.6 % to −19.7 % vs −2.0 % with placebo at 24 weeks; per-dose values come from the EASD 2026 abstract until the full text is available.
- UBT251 2.0 mg: Comparator semaglutide 1.0 mg: HbA1c −1.77 % Published in Cell Metabolism (26 October 2026, PMID 42933400): the abstract gives the HbA1c range across UBT251 arms (−2.16 to −1.98), semaglutide 1 mg −1.77 and placebo −0.66; per-arm weight and safety await the full text.
- UBT251 6.0 mg: Comparator semaglutide 1.0 mg: HbA1c −1.77 % Published in Cell Metabolism (26 October 2026, PMID 42933400): the abstract gives the HbA1c range across UBT251 arms (−2.16 to −1.98), semaglutide 1 mg −1.77 and placebo −0.66; per-arm weight and safety await the full text.
- 4.0 mg (initial dose 0.5 mg): Peer-reviewed paper (Cell Metab 2026) confirms the range of −13.6 % to −19.7 % vs −2.0 % with placebo at 24 weeks; per-dose values come from the EASD 2026 abstract until the full text is available.
- 4.0 mg (initial dose 0.5 mg): Published in Cell Metabolism (26 October 2026, PMID 42933400): the abstract gives the HbA1c range across UBT251 arms (−2.16 to −1.98), semaglutide 1 mg −1.77 and placebo −0.66; per-arm weight and safety await the full text.
- 4.0 mg (initial dose 1.0 mg): Published in Cell Metabolism (26 October 2026, PMID 42933400): the abstract gives the HbA1c range across UBT251 arms (−2.16 to −1.98), semaglutide 1 mg −1.77 and placebo −0.66; per-arm weight and safety await the full text.
Verbatim quotes from the source (8)
- UBT251 4.0 mg (start 1.0 mg) · weight_unsp · Results
LSM percentage change in weight
- UBT251 6.0 mg · weight_unsp · Results
LSM percentage change in weight
- UBT251 2.0 mg · weight_unsp · Results
LSM percentage change in weight
- UBT251 2.0 mg · hba1c · Results
LSM change in HbA1c
- UBT251 6.0 mg · hba1c · Results
LSM change in HbA1c
- 4.0 mg (initial dose 0.5 mg) · weight_unsp · abstract
change (95% CI) in weight being -13.6% (-15.3 to -11.8) in the 2.0 mg group, -16.2% (-18.7 to -13.6) in the 4.0 mg (ID, 0.5 mg)
- 4.0 mg (initial dose 0.5 mg) · hba1c · abstract
change in HbA1c was -2.16% (0.122), -1.98% (0.169), -2.08% (0.170) and -2.08% (0.118) with
- 4.0 mg (initial dose 1.0 mg) · hba1c · abstract
change in HbA1c was -2.16% (0.122), -1.98% (0.169), -2.08% (0.170) and -2.08% (0.118) with
Registered trials (6)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| UNISHAPE-OSA-1 UBT251 Injection Phase Ⅲ Study (OSA-NPAP) | Sleep apnoea | Phase 3 | not yet recruiting | 2026-12 → 2028-09 | 150 | not yet recruiting | NCT07767942 |
| UNISHAPE-OSA-2 UBT251 Injection Phase Ⅲ Study (OSA-PAP) | Sleep apnoea | Phase 3 | not yet recruiting | 2026-10 → 2029-03 | 150 | not yet recruiting | NCT07806851 |
| Overweight or Obesity UBT251 Injection Phase Ⅲ Study (Overweight or Obesity) | Obesity | Phase 3 | active not recruiting | 2026-09 → 2027-09 | 600 | active not recruiting | NCT07648225 |
| UNIGUIDE-1 Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone(UNIGUIDE-1) | T2D | Phase 3 | recruiting | 2026-09 → 2027-09 | 360 | recruiting | NCT07659574 |
| NCT07134335 UBT251 Injection Phase II Clinical Study (CKD) | CKD | Phase 2 | recruiting | 2025-09 → 2030-07 | 180 | recruiting | NCT07134335 |
| NCT07145151 A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) | MASH | Phase 2 | recruiting | 2025-09 → 2027-06 | 156 | recruiting | NCT07145151 |
Primary sources
- EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. Abstract easd63850.
- Zhou Z, Cheng Z, Jin P, Yang G, Wang H, Shi B, et al. UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial. Cell Metab. 2026. PMID: 42843337.
- Zhou Z, Shi X, Jiang S, Wang S, Shu H, Sun W, et al. UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with type 2 diabetes: A multicenter, randomized phase 2 trial. Cell Metab. 2026. PMID: 42933400.
How to cite this page
Cite the primary publication for any single result; every value above links to it.